Oncology decision-support market may reach $2.33 billion

ResearchAndMarkets.com said on Oct. 13 in a GlobeNewswire press release that the global oncology clinical decision-support market may reach $2.33 billion by 2036, from an estimated $0.71 billion in 2026.

The forecast implies a 12.6% compound annual growth rate over 2026-2036, ResearchAndMarkets.com said in the Oct. 13 press release. The annualized growth measure links the starting and ending values and points to rising software spending by hospitals, cancer centers and oncology clinics.

Oncology clinical decision support refers to software and related services that help clinicians use patient records, molecular test results and medical evidence when choosing cancer treatments. ResearchAndMarkets.com said adoption is being driven by precision oncology, biomarker-guided therapies, companion diagnostics, immunotherapies and targeted treatments.

The report said these platforms can analyze clinical records, genomic data, pathology results, imaging findings, biomarkers and therapeutic evidence. It said the tools support treatment selection, clinical-trial matching, medication management, risk assessment and long-term care planning.

Software is described in the report as the largest product and service segment, while services are expected to grow as health providers seek implementation, integration, customization, training, cloud migration and technical support. Treatment decision support is described as the largest application segment, while precision oncology and genomic interpretation are forecast to grow fastest.

Artificial intelligence, machine learning, deep learning, predictive analytics, natural-language processing and multi-omics analytics are among the technologies cited by ResearchAndMarkets.com. Multi-omics refers to the combined analysis of biological data types such as genomics and other molecular information.

The report also said integration with electronic health records, laboratory systems, pathology platforms, radiology systems, imaging archives, molecular diagnostics platforms and hospital information systems is improving clinical workflows. Cloud-based software-as-a-service deployment is described as supporting scale, interoperability, remote access and updates to clinical knowledge.

North America leads the market, according to the press release, supported by healthcare infrastructure, EHR adoption, genomic testing capacity, reimbursement conditions and oncology research investment. Europe is described as showing sustained growth through digital-health investment, precision-oncology initiatives, genomic-medicine programs and collaboration among hospitals, pharmaceutical companies and research institutions.

Asia-Pacific is projected by ResearchAndMarkets.com to grow fastest as cancer incidence rises and healthcare infrastructure, precision-medicine use, genomic testing capacity and government-backed digitalization expand across China, India, Japan, South Korea, Australia and Southeast Asia. The report also identifies developing opportunities in Latin America and the Middle East and Africa.

The press release lists Oracle Health, Elsevier, IBM, Tempus AI, Illumina, ConcertAI, Roche's Flatiron Health, GE HealthCare, Siemens Healthineers and Philips Healthcare among companies profiled in the report. It said competition depends on AI capabilities, genomic-interpretation expertise, clinical workflow integration, interoperability, cybersecurity, regulatory approvals and geographic reach.

ResearchAndMarkets.com also identified constraints that could slow adoption, including high implementation costs, legacy IT integration, data privacy requirements, cybersecurity risks, regulatory complexity, limited interoperability and concerns over algorithm transparency. It said healthcare organizations also need to manage physician acceptance, alert fatigue, workflow alignment and continuing clinical validation.

Source: promotional press release, GlobeNewswire/Research and Markets, Oct. 13, 2026